🤝 CIP supports companies 24+ months from investigational new drug submission. It offers regulatory expertise, lab access, and training.
🔬 The program connects developers with a cross-functional team for drug discovery and manufacturing. Interested parties can apply for the next cohort by March 2024.
Introduction:
The launch of the Charles River Incubator Program (CIP) marks a significant initiative aimed at fostering early-stage biotech companies in the development of innovative therapies. This program, introduced by Charles River Laboratories, seeks to provide essential resources and expertise to accelerate the discovery and manufacturing processes within the global biotechnology landscape.
- The CIP is designed to support early-stage biotech firms in the discovery, development, and manufacturing of advanced therapies, focusing on a timeline of 24+ months prior to investigational new drug (IND) or clinical trial application (CTA) submissions.
- This initiative builds upon the Charles River’s existing Cell and Gene Therapy (CGT) Accelerator Program, which caters to companies 18–24 months away from IND or CTA submission.
- The CIP provides participants with cost-effective regulatory and quality expertise, training initiatives, and access to essential laboratory space and equipment.
- It is supported by the Global Innovation Center of Excellence, which features a multidisciplinary team of specialists in drug discovery, safety assessment, and contract development and manufacturing.
- Charles River encourages interested developers to apply for participation and will evaluate candidates during industry events such as the Cell and Gene Therapy Summit and Advanced Therapies Week.
Conclusion:
The CIP represents a strategic step by Charles River Laboratories to enhance the support provided to early-stage biotech companies, potentially leading to accelerated therapeutic advancements and improved commercial viability. As the program seeks to incorporate new participants, it underscores the company’s ongoing commitment to innovation and collaboration within the biotechnology sector.
